Xencor, Inc. (NASDAQ:XNCR) Director Alan Bruce Montgomery Sells 13,301 Shares

Xencor, Inc. (NASDAQ:XNCR) Director Alan Bruce Montgomery sold 13,301 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the sale, the director now owns 9,140 shares of the company’s stock, valued at $247,054.20. The trade was a 59.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Alan Bruce Montgomery also recently made the following trade(s):

• On Wednesday, December 4th, Alan Bruce Montgomery sold 1,421 shares of Xencor stock. The stock was sold at an average price of $27.03, for a total value of $38,409.63.

Xencor Stock Performance

XNCR opened at $26.20 on Thursday. Xencor, Inc. has a one year low of $15.31 and a one year high of $27.24. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The business’s 50-day simple moving average is $22.31 and its 200-day simple moving average is $20.60.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the business posted ($0.40) EPS. The business’s revenue for the quarter was down 81.9% on a year-over-year basis. As a group, analysts forecast that Xencor, Inc. will post -3.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

XNCR has been the subject of several analyst reports. Royal Bank of Canada upped their target price on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. BMO Capital Markets restated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. JPMorgan Chase & Co. upped their target price on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their target price for the company from $20.00 to $30.00 in a report on Monday. Finally, Wedbush restated an “outperform” rating and issued a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $36.50.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Linden Thomas Advisory Services LLC grew its stake in Xencor by 1.6% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock worth $826,000 after buying an additional 699 shares during the last quarter. Baillie Gifford & Co. grew its stake in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 744 shares during the last quarter. Louisiana State Employees Retirement System grew its stake in Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 900 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in Xencor by 8.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 949 shares during the last quarter. Finally, Diversified Trust Co grew its stake in Xencor by 7.8% during the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock worth $266,000 after buying an additional 1,017 shares during the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.